Treating extrapyramidal syndrome using trapidil
Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.
1. A combination therapy method for treating or preventing a movement disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective combination of:
Trapidil, a derivative, a metabolite, or a pharmaceutically acceptable salt thereof; and
levodopa;
thereby treating or preventing the movement disorder in the subject;
2. The method of claim 1 , wherein the movement disorder is manifested as a dyskinesia, dystonia, akathisia, bradykinesia, tremors, or akinesia.
3. The method of claim 1 , wherein the movement disorder is associated with Parkinson's disease.
4. The method of claim 1 , wherein Trapidil is N,N-diethyl-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine.
5. The method of claim 1 , wherein the pharmaceutically acceptable salt of Trapidil comprises a salt with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, oxalic acid, malonic acid, or tartaric acid.
6. The method of claim 1 , wherein Trapidil or a pharmaceutically acceptable salt thereof and levodopa are administered simultaneously, sequentially, or at an interval period of time.
7. The method of claim 6 , wherein if sequentially, Trapidil or a pharmaceutically acceptable salt thereof is administered prior to administration of levodopa.
8. The method of claim 6 , wherein if sequentially, Trapidil or a pharmaceutically acceptable salt thereof is administered after the administration of levodopa.
9. The method of claim 1 , wherein Trapidil or a pharmaceutically acceptable salt thereof and levodopa are administered as a combined dosage form.
10. The method of claim 1 , wherein Trapidil or a pharmaceutically acceptable salt thereof and levodopa are each independently formulated for oral administration.
11. The method of claim 1 , wherein Trapidil or a pharmaceutically acceptable salt thereof and levodopa are each independently formulated for parenteral administration.
12. The method of claim 1 , wherein the subject is diagnosed with Parkinson's disease.
13. The method of claim 1 , wherein the combination therapy delays onset of the movement disorder in the subject.
14. The method of claim 1 , wherein Trapidil or a pharmaceutically acceptable salt thereof decreases the dose of levodopa administered to the subject relative to a dose of levodopa administered to the same subject in the absence of Trapidil or a pharmaceutically acceptable salt thereof.
15. The method of claim 1 , wherein Trapidil or a pharmaceutically acceptable salt thereof potentiate the effect of levodopa.
16. The method of claim 1 , wherein Trapidil or a pharmaceutically acceptable salt thereof is used as an adjuvant therapeutic agent.
17. The method of claim 1 , wherein the subject is a human.
18. The method of claim 1 , wherein the movement disorder is dyskinesia and the preventing is a delay in onset of dyskinesia or a slowing down of the progression of dyskinesia.
19. The method of claim 1 , wherein the therapeutically effective combination does not cause levodopa-induced dyskinesia in the subject.